Detalhe da pesquisa
1.
Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients.
BMC Infect Dis
; 22(1): 818, 2022 Nov 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36344927
2.
Effectiveness of subcutaneous monoclonal antibody treatment in emergency department outpatients with COVID-19.
J Am Coll Emerg Physicians Open
; 5(1): e13116, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38384380
3.
Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study.
Lancet Reg Health Am
; 31: 100693, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38500962
4.
Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
Lancet Infect Dis
; 23(6): 696-705, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36780912
5.
Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase.
Int J Infect Dis
; 128: 310-317, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36229005
6.
Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5.
Int J Infect Dis
; 132: 34-39, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37072054